Results 111 to 114 of about 5,034 (114)

Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index. [PDF]

RMD Open
Rosina S, Consolaro A, Pistorio A, Rebollo-Giménez A, Bracaglia C, Dolezalova P, Guilaisne Bernard-Medina A, Herlin T, Trachana M, Vargová V, Wouters C, Carenini L, Ruperto N, Ravelli A, Paediatric Rheumatology International Trials Organisation (PRINTO).   +14 more
europepmc   +1 more source

Increased vascular deposition of oxidized LDL in untreated juvenile dermatomyositis. [PDF]

Pediatr Rheumatol Online J
Spitznagle JC, Kacha-Ochana A, Cook-Mills JM, Morgan GA, Pachman LM.   +4 more
europepmc   +1 more source

Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies. [PDF]

Paediatr Drugs
Kim H.
europepmc   +1 more source

Successful treatment of an anti-MDA5 antibody-positive Juvenile Dermatomyositis patient with refractory interstitial lung disease using tofacitinib. [PDF]

Pediatr Rheumatol Online J
Natoli V, Palmeri S, Rebollo-Giménez AI, Matucci-Cerinic C, Bocca P, Caorsi R, Volpi S, Papa R, Consolaro A, Gattorno M, Ravelli A, Rosina S.   +11 more
europepmc   +1 more source